In this episode of Let’sTalk About That, Anirvan Ghosh speaks with Jason Coloma, CEO of Maze Therapeutics, about what it really takes to build a biotech company at the intersection of human genetics, precision medicine, and long-term value creation.

Jason brings a rare end-to-end perspective—spanning big pharma, venture creation, and public company leadership. The conversation traces how Maze was conceived at Third Rock Ventures around a simple but powerful idea: move beyond statistical genetic associations and use human genetics to deeply understand disease biology, identify protective variants, and design medicines that mimic nature’s own experiments.

Using kidney disease as a central case study, Jason explains how Maze translates genetic risk and protective variants into concrete drug targets—and why this approach may finally unlock progress in complex, common diseases that have resisted traditional drug discovery. The discussion also explores the realities of company building: choosing focus over breadth, making hard portfolio decisions in capital-constrained markets, partnering and spinning out programs, and navigating board and investor dynamics.

Jason reflects candidly on leadership under uncertainty, the challenges of going public in a volatile biotech market, and why clarity of vision matters more than consensus in leading a new company.